Abreos Biosciences has been awarded funding for phase two of the "Personalized precision dosing of anti-TNF biological therapies" project by, among others, the
Abreos Biosciences has been awarded funding for phase two of the "Personalized precision dosing of anti-TNF biological therapies" project by, among others, the
"This award allows us to continue this exciting and important project. Combined with our recent joint venture, Aegirbio, and the Magniareader platform it brings, we now have a clear scientific and commercial path to bring these tools to the patients that need them", say Abreos Biosciences CEO, Dr.
"We have here additional strong proof and support for the ideas behind the formation of Aegirbio. The market for Remicade/Infliximab is estimated to
For additional information please contact the CEO of
About LifeAssays®. NGM-listed LifeAssays® ABs business idéa is to develop, manufature and sell diagnostic systems based on the Company proprietary and patented technology platform, MagnetoImmunoAssay (MIA). The Company delivers safe and robust systems for quick and reliable analysis in human- and veterinay medicin. For more details please go to www.lifeassays.com
https://news.cision.com/lifeassays/r/abreos-gets-grant-of-850-000-usd-for-monitoring-of-crohns-disease,c3045106
(c) 2020 Cision. All rights reserved., source